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Establishing post mortem criteria 
for the metabolic syndrome: an autopsy based 
cross-sectional study
Martin Roest Christensen1*, Anne Bugge1,2, Mariam Elmegaard Malik1, Jørgen Lange Thomsen2, 
Niels Lynnerup1, Jørgen Rungby3 and Jytte Banner1
Abstract 
Background: Individuals who suffer from mental illness are more prone to obesity and related co-morbidities, 
including the metabolic syndrome. Autopsies provide an outstanding platform for the macroscopic, microscopic and 
molecular-biological investigation of diseases. Autopsy-based findings may assist in the investigation of the metabolic 
syndrome. To utilise the vast information that an autopsy encompasses to elucidate the pathophysiology behind the 
syndrome further, we aimed to both develop and evaluate a method for the post mortem definition of the metabolic 
syndrome.
Methods: Based on the nationwide Danish SURVIVE study of deceased mentally ill, we established a set of post mor-
tem criteria for each of the harmonized criteria of the metabolic syndrome. We based the post mortem (PM) evalua-
tion on information from the police reports and the data collected at autopsy, such as anthropometric measurements 
and biochemical and toxicological analyses (PM information). We compared our PM evaluation with the data from the 
Danish health registries [ante mortem (AM) information, considered the gold standard] from each individual.
Results: The study included 443 deceased individuals (272 male and 171 female) with a mean age of 50.4 
(± 15.5) years and a median (interquartile range) post mortem interval of 114 (84–156) hours. We found no significant 
difference when defining the metabolic syndrome from the PM information in comparison to the AM information 
(P = 0.175). The PM evaluation yielded a high specificity (0.93) and a moderate sensitivity (0.63) with a moderate level 
of agreement compared to the AM evaluation (Cohen’s κ = 0.51). Neither age nor post mortem interval affected the 
final results.
Conclusions: Our model of a PM definition of the metabolic syndrome proved reliable when compared to the AM 
information. We believe that an appropriate estimate of the prevalence of the metabolic syndrome can be established 
post mortem. However, while neither the PM nor the AM information is exhaustive in terms of defining an individual’s 
health status, a superlative estimate may be obtained by combining the PM and the AM information. With this model, 
we open up the possibility of utilising autopsy data for future studies of the metabolic syndrome.
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Background
Individuals with a severe mental illness (SMI), such as 
schizophrenia, bipolar disorder or major depression, 
constitute a part of the population that is more prone to 
suffer from obesity and the related co-morbidities [1–3]. 
The reasons for this are many-faceted and include socio-
economic factors, sedentary lifestyle, diet, smoking and 
medication [2–4]. It has been demonstrated repeatedly 
that the segment of the population with SMI suffers from 
metabolic syndrome (MetS) more frequently in compari-
son to the background population [1, 5–8].
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Metabolic syndrome is comprised of a cluster of revers-
ible risk factors that focus the attention of the clinician to 
patients with an increased risk of cardiovascular disease 
(CVD) and type 2 diabetes mellitus (DM). Several defini-
tions of MetS have been proposed by The World Health 
Organization, The International Diabetes Federation and 
the National Cholesterol Education Program [9–11]. In 
2009, the harmonized criteria of the MetS were proposed 
including central obesity, raised blood pressure, raised 
blood glucose, raised triglyceride level (TG), and/or low-
ered high density lipoprotein (HDL) cholesterol level, of 
which three have to be met for a person to be diagnosed 
with the MetS [12]. Individuals suffering from the MetS 
have double the risk of developing CVD and a five times 
increased risk of developing DM in comparison to the 
background population [12]. While some have argued for 
the dismissal of the MetS as a concept [13, 14], all of the 
major entities that have defined it recommend further 
research into it and the factors that dispose to CVD and 
diabetes [9, 11, 12].
An autopsy is widely considered the ultimate diagnos-
tic tool and several studies have demonstrated the benefit 
of autopsies in diagnosing overlooked diseases [15–17]. 
Hereditary heart diseases and the ‘Back to Sleep’ cam-
paign in sudden infant death syndrome are just some of 
the examples of autopsy based diagnostics and epide-
miology of the dead that have prevented morbidity and 
mortality [18–20].
The aim of this study was to define and evaluate the 
post mortem (PM) criteria of the MetS, based on the 
Danish autopsy-based SURVIVE study [21]. Establish-
ing well-defined PM criteria will make it possible to link 
the morbidity and mortality determined at the autopsy 
to the MetS and thereby exploit the potential of the 
autopsy data in elucidating diagnostics, pathophysiology 
and potential treatment of the MetS. To accomplish this 
goal, we focused on specific autopsy related data (police 
reports, biochemical and toxicological results; i.e. PM 
information) and we tested it against registry data [diag-
nosis codes and prescribed medication; i.e. ante mortem 
(AM) information].
Methods
Study population
The SURVIVE study [21] included all of the deceased per-
sons, over a 2-year period in Denmark, with a known or 
suspected psychiatric disease (ICD10 F1–F6, F9) where 
a forensic autopsy was performed. The deceased were 
included from May 2013 to May 2015 at all three Depart-
ments of Forensic Medicine. The exclusion criteria were: 
(1) moderate to advanced putrefaction, (2) computed 
tomography (CT) scan prior to autopsy not performed, 
and (3) cases of homicide or suspected homicide. We 
retrieved information from the general practitioner (GP) 
regarding the deceased’s health status and medication 
from the police reports concerning the death of each 
individual. We accessed the Danish National Health Reg-
istries and, based on the social security number, retrieved 
the hospital ICD10 diagnosis codes from 1994 to the 
time of death and the prescribed medication for each 
individual.
A total of 500 deceased were included in the SURVIVE 
study. In accordance with Danish legislation, the next 
of kin were contacted and consent was obtained in 443 
cases (male = 272; female = 171). The ethnicities of the 
decedents included 435 Caucasians, 5 Africans, 2 Inuit 
(Greenlanders) and 1 of Middle Eastern origin. We calcu-
lated the post mortem interval (PMI) in a similar fashion 
to Holm and Linnet [22], as half the time from the dece-
dent was last seen alive to he/she was found dead plus the 
time to autopsy. In cases were death was witnessed, we 
only used the time from death to autopsy.
The study was approved by the Danish National 
Committee on Health Research Ethics (Case Num-
ber: 1305373) and the National Danish Data Protection 
Agency (case number: SUND-2016-06).
Anthropometry and biochemical parameters
Anthropometric measurements were recorded during the 
forensic autopsy. The height of the deceased was meas-
ured in a supine position and the weight was recorded 
with the decedent naked. The standard waist circumfer-
ence (WC) was measured halfway between the superior 
iliac crest and the costal margin [23] and a conversion 
factor for the WC measurements from the supine to the 
standing position was applied [24]. The heart was trans-
versally sectioned from the apex to the mid-ventricular 
level. The left ventricular wall thickness of the anterior, 
lateral and posterior part was measured at the mid-ven-
tricular level, according to international standards [25].
During the autopsy, when possible, peripheral blood 
from the internal femoral artery was gathered; if this was 
not possible, central blood from the heart was sampled. 
Urine samples were also gathered. A total of 364 blood 
samples and 248 urine samples were collected; the sam-
ples were stored in vials with no additives at − 20  °C or 
− 80 °C until analysis.
We measured the total cholesterol and triglycerides 
(TG) using a  Reflotron® Plus (Roche, Basel, Switzerland). 
Glycated haemoglobin (HbA1C) in the blood and the 
urine albumin/creatinine ratio were measured using a 
Siemens DCA  Vantage® immuno-assay (Siemens, Erlan-
gen, Germany). Standard toxicological analyses of the 
blood samples were performed, using ultra performance 
liquid chromatography with tandem mass spectrometry 
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(UPLC MS/MS), to detect the presence of medications 
related to the MetS (Table 1).
Registry data
Using the National Danish Health Registry, we searched 
for diagnosis codes corresponding to each of the MetS 
criteria except waist circumference. Based on the Danish 
National Treatment Recommendations [26], we identi-
fied whether a deceased had MetS related medication 
prescribed within the 6 months prior to death (Table 1).
Post mortem definition of the MetS
We cross-referenced the PM information with the AM 
information, as shown in Table  2. If just one of the PM 
criteria in groups 2–5 (Table  2) were met, the corre-
sponding AM criterion was assumed to be fulfilled. A 
deceased was classified as having the MetS if three or 
more of the AM criteria were present, according to the 
harmonized criteria [12]. The cut-off values for total 
cholesterol, TG, and HbA1C were selected based on the 
definition of pre-diabetes and the Danish National Treat-
ment Guidelines [27–29]. The urine albumin/creatinine 
ratio and the left ventricular hypertrophy (LVH) were 
used as proxy markers for hypertension when underly-
ing kidney disease (ICD10 N0–N2) and cardiomyopathy 
(ICD10 I42–I43), respectively, had been excluded [24, 
25].
Statistical analysis
Each of the criteria, except the WC, based on the PM 
information were compared with the corresponding 
AM information, as the gold standard. Reproducibility 
was determined using Cohen’s kappa with agreement 
assessed according to Landis and Koch [30]. McNe-
mar’s test was used for the contingency tables of the 
paired samples. To evaluate our PM MetS criteria fur-
ther, sensitivity, specificity, and the likelihood ratio (LR) 
were calculated. A Student’s t test and a Wilcoxon rank 
sum test were used for parametric and non-parametric 
data, respectively. Pearson’s r was determined to assess 
Table 1 Specifications for registry searches
Clinical diagnoses related to the MetS with the corresponding ICD10 codes, the medication and the ATC-codes used to define the presence and/or treatment of the 
MetS. The ATC-codes are based on the Danish National Treatment Guidelines
Metabolic syndrome criteria ICD-10 codes Medication groups ATC-codes
Hypertriglyceridemia DE781 Fibrates, Nicotinic acid C10AB
Hypercholesterolemia DE780 Statins, Cholestyramine, Cholesterol absorption 
inhibitors
C10AA, C10AC, C10AX
Hypertension DI10–DI15 Thiazide,  Ca2+-antagonists, ACE inhibitors, Angio-
tensin II receptor blockers, Renin inhibitors, 
β-blockers, α-blockers, Hydralazine, Centrally 
active (Moxonidine)
C02AB, C02AC, C02CA, C02DB, C03, C07A, C08, 
C09A, C09C, C09X
Elevated blood glucose DE10–DE14 Β-cell stimulants, α-glucosidase inhibitors, 
Glitazones, DPP-IV-inhibitors, GLP1-analogs, 
SGLT2-inhibitors
A10B
Table 2 Harmonized criteria for the metabolic syndrome and the corresponding post mortem criteria
HbA1C glycated haemoglobin, HDL high density lipoprotein, PM post mortem, TG triglyceride
Ante mortem criteria Post mortem criteria
1 Waist circumference (≥ 94 cm men; ≥ 80 cm women) Supine waist circumference with conversion factor (≥ 94 cm men; ≥ 80 cm women)
2 Increased TG or treatment hereof Information from the police report
Medication in the PM-toxicology
Increased TG in the PM-biochemistry (≥ 1.7 mmol/L)
3 Decreased HDL-cholesterol or treatment hereof Information from the police report
Medication in the PM-toxicology
Increased total cholesterol in the PM-biochemistry (≥ 5.0 mmol/L)
4 Hypertension or treatment hereof Information from the police report
Medication in the PM-toxicology
Left ventricular wall thickness (≥ 15 mm)
Increased urine albumin/creatinine ratio in the PM-biochemistry (> 30 mg/g)
5 Increased fasting blood glucose or treatment hereof Information from the police report
Medication in the PM-toxicology
Increased HbA1C in the PM-biochemistry (> 38 mmol/mol)
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correlations. A P value <0.05 was considered significant. 
All statistical analyses were performed using R v. 3.4.0 
[31].
Results
The mean (± SD) age of the study population was 50.4 
(± 15.5) years with men being significantly younger than 
women (men: 48.0 [± 14.2] years; women: 54.3 [± 16.6] 
years; P < 0.001). We determined a median PMI (inter-
quartile range) of 114 (84–156) hours. We were unable 
to determine the PMI in 72 cases. All ethnicities fell 
within the same reference measurement of the WC, as 
stated by the IDF (≥ 94  cm men; ≥ 80  cm women). The 
basic anthropometric and biochemical data are listed in 
Table 3. Adjusting for age in Table 3 did not produce sig-
nificant differences in either criteria (data not shown). 
Investigating the effect of PMI on the biochemical meas-
urements, we found a significant correlation with TG 
(r =0.22, P < 0.001) but no significant correlations for the 
other criteria (total cholesterol: r =− 0.14, P = 0.07. Albu-
min/creatinine ratio: r =0.02, P = 0.78. HbA1c: r = − 0.01, 
P = 0.82). From the autopsy reports, we concluded that 
none of the deceased with LVH or an elevated albumin/
creatinine ratio suffered from cardiomyopathy or kidney 
disease.
We compared our PM definition of the MetS with each 
of the proposed PM criteria, based on the PM informa-
tion, with the corresponding AM definition and infor-
mation. The reproducibility of our combined PM MetS 
definition resulted in a moderate agreement (κ = 0.51). 
For the criteria regarding the TG, total cholesterol, 
hypertension and blood glucose, the agreement ranged 
from slight to moderate (Table  4). Information on the 
WC was only available from the PM information and was 
thus omitted from Tables 4 and 5. 
We found no significant difference when we estimated 
the MetS based only on the PM information, in com-
parison to estimating the MetS based only on the AM 
information (Table 5). Our PM definition resulted in high 
specificity (0.93) and moderate sensitivity (0.63) with a 
reasonable likelihood ratio (LR) (9.27) (Table 5).
The biochemical measurements of the PM TG were 
high when compared to the cut-off value (Table  3). 
Although using the PM triglyceride biochemistry results 
for the triglyceride criteria produced no false nega-
tive results, hence the perfect sensitivity, this yielded an 
immense overestimation. Omitting the PM triglyceride 
biochemistry results produced a far more accurate esti-
mation, with no significant difference, between the PM 
and the AM information. None of the deceased had a 
total cholesterol level above 4.0 mmol/L in the PM bio-
chemical analyses. Therefore, using only the PM informa-
tion for the cholesterol criteria resulted in a significant 
underestimation of that criterion. Conversely, using only 
the PM information on the hypertension and glucose cri-
teria significantly overestimated those criteria.
Discussion
To our knowledge, this is the first study that defined the 
criteria for the diagnosis of the MetS in a post mortem 
perspective.
We opted to use the AM information from the regis-
tries as the gold standard. A priori, the specificity of this 
information is close to one. The registry information is, 
however, not exhaustive regarding an individual’s health 
status. Only diagnoses from hospital admissions were 
recorded; diagnoses from the GPs of the individual sub-
jects were not available through our registries. Con-
versely, in a forensic autopsy setting, access is available to 
the police reports, which include the police questioning 
of the GPs regarding a decedent’s health status. Although 
this information might not be exhaustive, it may be 
regarded as information with a high specificity. The regis-
try information regarding prescribed medication reflects 
the diagnoses that a GP finds appropriate to treat and is 
consequently an indirect source for measuring a person’s 
Table 3 Anthropometry and biochemical results related to the metabolic syndrome
The lower quantification limits for triglycerides was 0.8 mmol/L and it was 3.00 mmol/L for total cholesterol. The upper quantification limit for total cholesterol was 
6.8 mmol/L. Not all blood samples could be analysed for triglycerides or cholesterol. The waist circumference is expressed as mean (95% CI). The remaining values are 
expressed as median (interquartile range). Adjusting for age did not affect the results
a Blood samples
b Urine samples
Metabolic syndrome criteria Men Women N (male/female) P value
Waist circumference (cm), converted 97.3 (95.3; 99.3) 94.2 (91.3; 97.0) 443 (272/171) 0.08
Triglycerides (mmol/L)a 2.90 (2.60; 3.40) 3.00 (2.60; 3.45) 308 (185/123) 0.39
Total cholesterol (mmol/L)a 3.00 (< 3.00; 3.20) 3.10 (< 3.00; 3.2) 216 (90/126) 0.11
Albumin/creatinine  ratiob 16.36 (7.88; 49.91) 22.35 (12.02; 67.59) 248 (75/173) 0.11
Glycated haemoglobin (mmol/mol)a 32 (29; 36) 33 (29; 37) 364 (140/224) 0.67
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health status. A caveat when defining the health status of 
individuals with SMI from registries or GPs is that the 
prevalence of dyslipidaemia and hypertension are fre-
quently underestimated and undertreated [32]. Although 
our proposed PM definition of the MetS was not signifi-
cantly different from the AM definition, it yielded only 
a moderate level of agreement. While there were some 
gender differences in Cohen’s κ for some of the individ-
ual criteria, the gender-specific agreement in the final 
PM model was quite similar. Since the prevalence of the 
MetS in our study cohort is relatively low, the calculated 
Cohen’s κ might underestimate the actual agreement 
between the PM and the AM definition and criteria [33]. 
Therefore, the sensitivity and specificity may reflect the 
most correct estimate of agreement. Again, no gender 
differences regarding sensitivity and specificity were evi-
dent. In addition, since the information originates from 
different sources in our setup, comparing the PM infor-
mation with the AM information will generally produce 
some discrepancies. Consequently, one should regard the 
level of agreement with some reservations.
Measuring and interpreting the PM biochemical 
analyses posed several challenges. The total cholesterol 
decreases PM leaving only elevated concentrations inter-
pretable [34, 35]. Since none of our subjects had a total 
cholesterol above 4.0  mmol/L, our findings may cor-
roborate the challenge of analysing cholesterol in PM 
samples. The levels of PM TG have been reported to be 
affected by too many variables to make it useful for inter-
pretation [34, 35]. In line with the study by Girard et al. 
Table 4 PM MetS estimation and individual criteria compared to the AM definition and corresponding criteria
Due to restrictions from statistics Denmark regarding the disclosure of aggregated microdata (N ≤ 3), the table regarding the triglyceride criterion has been omitted 
and NAs used in appropriate fields in the other criteria
MetS metabolic syndrome
Combined MetS definition Ante Mortem Cohen’s κ (male/female)
MetS yes (male/female) MetS no (male/female)
Post mortem
 MetS yes 29 (16/13) 27 (14/13) 0.51 (0.56/0.45)
 MetS no 17 (7/10) 370 (235/135)
 Individual criteria Criterion met Criterion not met  Cohen’s κ (male/female)
Post mortem
 Triglycerides NA NA 0.19 (NA/NA)
 Total cholesterol Criterion met 18 (13/5) 7 (NA) 0.36 (0.47/0.22)
Criterion not met 44 (21/23) 374 (234/140)
 Hypertension Criterion met 103 (55/48) 153 (106/47) 0.24 (0.19/0.33)
Criterion not met 26 (14/12) 161 (97/64)
 Blood glucose Criterion met 34 (18/16) 40 (21/19) 0.55 (0.54/0.56)
Criterion not met 5 (NA) 364 (229/135)
Table 5 Evaluation of the PM definition of the metabolic syndrome and individual criteria
All results are evaluated comparing the PM definition or criterion to the AM definition and the corresponding criterion. Gender-specific sensitivity and specificity for 
triglycerides was not calculated due to restrictions from Statistics Denmark regarding disclosure of aggregated microdata (N < 3)
AM ante mortem, CI confidence interval, MetS metabolic syndrome, PM post mortem, w/o without
Sensitivity (male/female) Specificity (male/female) Likelihood ratio (95% 
CI)
Difference PM vs. AM 
(95% CI)
P value
PM definition MetS 0.63 (0.70/0.57) 0.93 (0.94/0.91) 9.27 (6.05; 14.19) 2.3% (− 0.7%; 5.2%) 0.175
PM cholesterol 0.29 (0.38/0.17) 0.98 (0.98/0.98) 15.80 (6.89; 36.27) − 8.4% (− 11.4%; − 5.3%) < 0.001
PM hypertension 0.80 (0.80/0.80) 0.51 (0.48/0.58) 1.64 (1.42; 1.89) 34.5% (29.3%; 39.8%) < 0.001
PM triglycerides 1 (NA/NA) 0.30 (NA/NA) 1.42 (1.34; 1.51) 70.0% (65.7%; 74.2%) < 0.001
PM triglycerides w/o PM 
biochemistry
0.50 (NA/NA) 0.98 (NA/NA) 31.50 (6.65; 151.21) 1.4% (0.1%; 2.6%) 0.077
PM glucose 0.87 (0.82/0.94) 0.90 (0.92/0.88) 8.81 (6.41; 12.10) 7.9% (5.0; 10.8%) < 0.001
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[35], the measured TG in our study increased with PMI. 
Moreover, the reference values of cholesterol and TG in 
the living are frequently based on a premise of fasting. 
We concluded that total cholesterol and TG were impre-
cise parameters and omitted them from our final MetS 
estimation. While direct measurement of blood glucose 
levels PM is not feasible [36], several studies have proven 
HbA1C as a robust marker of long-term blood glucose 
status in PM measurements [34, 36–40]. As we used an 
immune-assay to measure HbA1c, our results might be 
biased towards higher values due to diminished specific-
ity compared to chromatographic measurements [36]. 
Our PM information differed significantly from the AM 
information. Although this could be a result of underre-
ported and undertreated hyperglycaemia in people with 
SMI [32], it may reflect the fact that our cut off value of 
38 mmol/mol does not yield an ICD10 code of diabetes 
in a clinical setting; contributing to our PM definition 
overestimating the prevalence of this criterion.
Diagnosing hypertension at autopsy can be problem-
atic. Few markers exist and they rely on the exclusion of 
other diseases. In hypertension, the myocytes in the left 
ventricle of the heart undergo hypertrophy. Although it 
manifests most frequently as concentric hypertrophy, it 
can also present as eccentric hypertrophy. While other 
diseases may affect the pattern of hypertrophic response, 
hypertension is still a part of these conditions [41]. When 
it comes to ruling out cardiomyopathies, autopsy data, 
specifically histology, provides one of the hallmarks of 
diagnosing these diseases. Therefore, we considered LVH, 
excluding cardiomyopathies, as an appropriate marker 
for hypertension.
The WC was the only criterion that we were unable to 
validate with AM information. However, as one of the 
exclusion criteria was moderate to advanced putrefac-
tion, cases with markedly PM bloating of the abdomen 
were not included. In addition, the use of a conversion 
factor from the supine to the standing position [24] fur-
ther corrected the estimated WC.
Selection bias must be considered since the study is 
based on forensic autopsy material. A forensic autopsy 
is performed on request from the police in cases of acci-
dents, suicides, (suspected) homicides and when the 
manner and/or cause of death remains unknown at the 
medico-legal examination. Therefore, the results are in 
line with most other study populations based on forensic 
autopsies that are descriptive for a specific study popu-
lation and not necessarily representative for the general 
population. In such a study population, a precise setup of 
inclusion criteria—such as age, gender, specific diagno-
sis and equivalent healthy controls—may accommodate 
some of the selection bias. Furthermore, as the pre-
sent study was based on a study population of deceased 
individuals with SMI, we cannot rule out the possibility 
of a different result if the PM model was employed on 
deceased mentally healthy individuals. However, with the 
aforementioned underestimation and undertreatment 
of dyslipidaemia in individuals with SMI [32], the evalu-
ation of the PM model based on individuals with SMI 
might actually underestimate the specificity of the model 
compared to the same evaluation based on a mentally 
healthy study population.
Conclusions
With this study, we proposed a valid estimate for the 
PM diagnosis of the MetS. While neither the PM nor 
the AM information are exhaustive regarding an indi-
vidual’s health status, combining both the PM and the 
AM information might provide the best estimation. 
However, bearing in mind that the result is an approxi-
mation and not a conclusive answer, employing PM 
information alone is applicable. Although PM TG and 
total cholesterol measurements are unreliable and should 
be omitted, PM HbA1C remains a valid measurement. 
Employing autopsy material and our PM MetS definition, 
we believe that autopsy-based data may promote the 
research of the MetS and associated morbidities from a 
novel perspective.
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